SCHEMBL4272298

SCHEMBL4272298

O=C(O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3)cnc12

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.61
NPC1 O15118 8/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
KDM4E B2RXH2 6/20 0.61
ALDH1A1 P00352 5/20 0.61
MAPT P10636 4/20 0.61
LMNA P02545 3/20 0.49
POLB P06746 2/20 0.49
RXFP1 Q9HBX9 2/20 0.48
TDP1 Q9NUW8 1/20 0.47
HPGD P15428 2/20 0.45
TP53 P04637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDR P35968 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
GPR119 Q8TDV5 3/20 0.44
AHR P35869 1/20 0.41
HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275323 0.96 RAB9A (0.57) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2083955 0.87 RAB9A (0.51) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2086764 0.85 RAB9A (0.49) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14014378 0.84 KDM4E (0.65) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4710751 0.83 KDM4E (0.57) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL1754478 0.83 RAB9A (0.46) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4127132 0.83 RAB9A (0.47) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL4707200 0.81 KDR (0.44) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14014409 0.81 KDM4E (0.49) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14014492 0.81 KDM4E (0.49) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD RAB9A 364/4885NPC1 3153/4885SMN1; SMN2 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.